➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Johnson and Johnson
Express Scripts
Baxter
Medtronic

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

MYCOSTATIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Mycostatin patents expire, and what generic alternatives are available?

Mycostatin is a drug marketed by Delcor Asset Corp and is included in seven NDAs.

The generic ingredient in MYCOSTATIN is nystatin. There are eight drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the nystatin profile page.

US ANDA Litigation and Generic Entry Outlook for Mycostatin

A generic version of MYCOSTATIN was approved as nystatin by FOUGERA PHARMS on September 23rd, 1982.

  Start Trial

Summary for MYCOSTATIN
Drug patent expirations by year for MYCOSTATIN
Recent Clinical Trials for MYCOSTATIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 2
M.D. Anderson Cancer CenterPhase 2
National Taiwan University HospitalPhase 2

See all MYCOSTATIN clinical trials

US Patents and Regulatory Information for MYCOSTATIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Delcor Asset Corp MYCOSTATIN nystatin CREAM;TOPICAL 060575-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Delcor Asset Corp MYCOSTATIN nystatin TABLET;VAGINAL 060577-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Delcor Asset Corp MYCOSTATIN nystatin POWDER;TOPICAL 060578-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Harvard Business School
Express Scripts
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.